Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 6Terminated 2Recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 451Gastrointestinal 89Breast 85Gynecologic 77Genitourinary 73Head & Neck 62Dermatologic 43Sarcoma 30CNS 26Other solid neoplasm 25Lymphoid 23Other hematologic neoplasm 22Endocrine 13Plasma cell 12Other neoplasm 4Myeloid 4Classical hematology 3Other 2NET 1

Conditions

Neuroendocrine Tumors 208Carcinoid Tumor 26Neoplasms 22Pancreatic Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 14Carcinoma, Neuroendocrine 11Carcinoma 11Adenoma, Islet Cell 11Neoplasm Metastasis 10Colorectal Neoplasms 9Lung Neoplasms 8Serotonin Syndrome 7Prostatic Neoplasms 7Adenocarcinoma 7Pheochromocytoma 6Gastrointestinal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Somatostatinoma 5Neuroblastoma 5Melanoma 5Gastroenteropancreatic Neuroendocrine Tumors 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Vipoma 4Sarcoma 4Rectal Neoplasms 4Paraganglioma 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × NET × Clear all
NCT02936323 2021-12-14

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Tarveda Therapeutics

Phase 1/2 Completed
89 enrolled 30 charts
EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡